7 Einträge gefunden

1. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

   1. Gordon, Kenneth B
   2. Foley, Peter
   3. Krueger, James G
   4. Pinter, Andreas
   5. Reich, Kristian
   6. Vender, Ronald
   7. Vanvoorden, Veerle

   2021 - Forschungsinformationssystem des UKE
2. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

   1. Reich, Kristian
   2. Armstrong, April W
   3. Foley, Peter
   4. Song, Michael
   5. Miller, Megan
   6. Shen, Y K
   7. You, Yin

   2020 - Forschungsinformationssystem des UKE
3. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

   1. Deleuran, Mette
   2. Thaçi, Diamant
   3. Beck, Lisa A
   4. de Bruin-Weller, Marjolein
   5. Blauvelt, Andrew
   6. Forman, Seth
   7. Bissonnette, Robert

   2020 - Forschungsinformationssystem des UKE
4. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

   1. Reich, Kristian
   2. Foley, Peter
   3. Han, Chenglong
   4. McElligott, Sean
   5. Muser, Erik
   6. Li, Nan
   7. Armstrong, April W

   2020 - Forschungsinformationssystem des UKE
5. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

   1. Leonardi, Craig
   2. Reich, Kristian
   3. Foley, Peter
   4. Torii, Hideshi
   5. Gerdes, Sascha
   6. Guenther, Lyn
   7. Gooderham, Melinda

   2020 - Forschungsinformationssystem des UKE
6. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

   1. Gordon, Kenneth B
   2. Armstrong, April W
   3. Foley, Peter
   4. Song, Michael
   5. Shen, Yaung-Kaung
   6. Li, Shu
   7. Muñoz-Elías, Ernesto J

   2019 - Forschungsinformationssystem des UKE
7. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

   1. Gordon, Kenneth B
   2. Strober, Bruce
   3. Lebwohl, Mark
   4. Augustin, Matthias
   5. Blauvelt, Andrew
   6. Poulin, Yves
   7. Papp, Kim A

   2018 - Forschungsinformationssystem des UKE